Top Markets
#1 Cross Cross +15.68%
#2 Gama Token Gama Token +8.43%
#3 Glidr Glidr +5.05%
#4 Humanity Humanity +5.03%
#5 TDCCP TDCCP +4.85%
#6 龙虾 (Lobster) 龙虾 (Lobster) +4.82%
#7 Akedo Akedo +4.60%
#8 LEO Token LEO Token +4.58%
#9 Pieverse Pieverse +4.12%
#10 Berachain Berachain +3.39%
Coin of the day
Cross Cross
Settings
Language
ENGLISH
Currency
USD
Theme
Guard Therapeutics International AB (publ) Guard Therapeutics International AB (publ)

Guard Therapeutics International AB (publ)

GUARD
Rank in Stocks #36113
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company... Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Share Price
$0.14966934
Last synced: 2026-08-14
Market Cap
$3.02M
Change (1 day)
3.72%
Change (1 year)
-93.70%
Country
SE
Trade Guard Therapeutics International AB (publ) (GUARD)

Category

Healthcare
Earnings for Guard Therapeutics International AB (publ) (GUARD)
Earnings in 2026 TTM: 0
According to Guard Therapeutics International AB (publ) latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Guard Therapeutics International AB (publ) from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE